|
|Section2= |Section3= }} XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial which works via weakening bacteria cell walls.〔 It is a potential treatment for methicillin-resistant ''Staphylococcus aureus'' (MRSA) and possibly ''Clostridium difficile''. It is being developed by Destiny Pharma Ltd.〔(Destiny Pharma - XF-73 ) (shows molecular structure)〕〔(European Society of Clinical Microbiology and Infectious Diseases. XF-73 ), Apr 2008〕〔(Scientists 'on brink of cure' for superbug ), ''The Independent'', 18 May 2008〕 It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.〔(Promising new drug XF-73 kills superbugs within 5 minutes ), 20 Sept 2010〕〔(MRSA: UK scientists 'close to a treatment ), ''The Daily Telegraph''〕 Structurally it is a dicationic porphyrin.〔(Destiny Pharma - XF series )〕 ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「XF-73」の詳細全文を読む スポンサード リンク
|